GRAIL Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics:

Total Revenue: $44.7 million, up 26% year-over-year.

Screening Revenue: $42.6 million, a 24% increase from Q2 2025.

Test Volume: Over 61,000 Galleri tests sold, a 35% increase year-over-year.

Net Loss: $110.2 million, a 3% decrease compared to Q2 2025.

Adjusted Gross Profit: $21.6 million, a 34% increase year-over-year.

Adjusted EBITDA: Negative $90.3 million, an increase in loss of 15% compared to the previous year.

Cash Position: $861.6 million, bolstered by a $110 million strategic investment from Samsung.

2Strategic Updates and Business Highlights:

GRAIL continues to expand the Galleri test, which has shown strong performance in clinical trials, including the PATHFINDER 2 and NHS-Galleri studies.

The Galleri test has a false positive rate of less than 0.5%, significantly lower than competitors.

A collaboration with Samsung C&T Corporation aims to commercialize Galleri in South Korea, with potential expansion into Japan and Singapore.

The company has expanded its field sales and medical teams, which are now fully operational following positive clinical data presentations.

GRAIL is actively pursuing FDA approval for Galleri, with a premarket approval application submitted and an advisory committee meeting anticipated in the fall.

3Forward Guidance and Outlook:

GRAIL expects continued growth in Galleri sales, with revenue growth of 30% year-over-year anticipated for the first half of 2026.

The company remains optimistic about achieving FDA approval in early 2027, which is expected to enhance payer and provider confidence in Galleri.

Future publications of clinical trial results are anticipated, which may further support market adoption.

4Bad News, Challenges, or Points of Concern:

The primary endpoint for the NHS-Galleri trial was not met, which could impact perceptions of the test's efficacy despite other positive results.

The competitive landscape is evolving, with other MCED tests entering the market, potentially causing confusion among physicians and impacting pricing strategies.

Regulatory uncertainties remain, particularly regarding the timing of the FDA advisory committee meeting and subsequent CMS coverage decisions, which could delay broader adoption.

Ongoing organizational changes within the NHS may hinder future collaborations and decision-making processes in the UK.

5Notable Q&A Insights:

GRAIL's leadership expressed confidence in the upcoming FDA advisory committee meeting, indicating that they are well-prepared for potential questions.

There is speculation about whether CMS will wait for FDA approval before defining coverage criteria for MCED tests, with GRAIL assuming that national coverage analysis will follow FDA approval.

The sales force expansion was driven by positive clinical data, and initial feedback from physicians has been favorable, indicating strong market interest.

Discussions about potential future collaborations with the NHS are ongoing, but organizational upheaval is currently causing delays in decision-making. Overall, GRAIL's Q2 2026 results reflect strong growth in Galleri sales and strategic advancements towards regulatory approval, though challenges in the competitive landscape and regulatory environment remain.